Chemotherapy-induced Peripheral Neuropathy Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Chemotherapy-induced Peripheral Neuropathy Pipeline Insight 2025" report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Chemotherapy-induced Peripheral Neuropathy pipeline landscape. It covers the Chemotherapy-induced Peripheral Neuropathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chemotherapy-induced Peripheral Neuropathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Chemotherapy-induced Peripheral Neuropathy Pipeline. Dive into DelveInsight's comprehensive report today! @ Chemotherapy-induced Peripheral Neuropathy Pipeline Outlook [https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chemotherapy-induced Peripheral Neuropathy Pipeline Report

* In May 2025, Ono Pharmaceutical Co., Ltd conducted a Phase II Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel.
* In May 2025, Dogwood Therapeutics Inc . announced a Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain.
* In May 2025, Eli Lilly and Company announced a study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.
* DelveInsight's Chemotherapy-induced Peripheral Neuropathy Pipeline report depicts a robust space with 4+ active players working to develop 5+ pipeline therapies for Chemotherapy-induced Peripheral Neuropathy treatment.
* The leading Chemotherapy-induced Peripheral Neuropathy Companies such as Grunenthal GmbH, AlgoTherapeutix, Wex Pharmaceuticals Inc., and others.
* Promising Chemotherapy-induced Peripheral Neuropathy Pipeline Therapies such as LY3848575, Pregabalin, Oxaliplatin, Targin, Chemotherapy, Halneuron, Acetylcarnitine, and others.

Stay ahead with the most recent pipeline outlook for Chemotherapy-induced Peripheral Neuropathy. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chemotherapy-induced Peripheral Neuropathy Treatment Drugs [https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chemotherapy-induced Peripheral Neuropathy Emerging Drugs Profile

* Capsaicin: Grunenthal GmbH

Capsaicin (QUTENZA) is a specially formulated topical system that delivers prescription-strength capsaicin directly to the skin during an in-office procedure. This way, it can reversibly desensitise and defunctionalise the TRPV1 (Transient Receptor Potential Vanilloid 1) receptor, which plays a critical role in pain signalling. QUTENZA administered as a single localised procedure can provide sustained pain relief that lasts for up to three months. It has no known drug-drug interactions. The most common adverse reactions include application site reactions, such as erythema, pain, and pruritus. Currently, the drug is in Phase III stage of its development for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN).

* ATX01: AlgoTherapeutix

ATX01 targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channels. It has been designed to provide targeted relief from excruciating pain in the feet and hands of patients suffering from Chemotherapy-Induced Peripheral Neuropathy (CIPN). ATX01 has wide potential applicability beyond CIPN, in other diseases where peripheral neuropathic pain is a major issue. By applying the ATX01 hydrogel to the skin, the active ingredient is locally delivered to the nerve endings where pain signals originate and propagate alongside the neurons to the central nervous system. This method of application is especially relevant to CIPN which involves localized pain. Topical administration also minimizes systemic toxicity and drug interactions through limited systemic exposure, which is particularly important in patients exposed to chemotherapy. Currently, the drug is in Phase II stage of its development for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN).

The Chemotherapy-induced Peripheral Neuropathy Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy-induced Peripheral Neuropathy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy-induced Peripheral Neuropathy Treatment.
* Chemotherapy-induced Peripheral Neuropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chemotherapy-induced Peripheral Neuropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy-induced Peripheral Neuropathy market

Explore groundbreaking therapies and clinical trials in the Chemotherapy-induced Peripheral Neuropathy Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Chemotherapy-induced Peripheral Neuropathy Drugs [https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chemotherapy-induced Peripheral Neuropathy Companies

Grunenthal GmbH, AlgoTherapeutix, Wex Pharmaceuticals Inc., and others.

Unveil the future of Chemotherapy-induced Peripheral Neuropathy Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chemotherapy-induced Peripheral Neuropathy Market Drivers and Barriers

Scope of the Chemotherapy-induced Peripheral Neuropathy Market Report

* Coverage- Global
* Chemotherapy-induced Peripheral Neuropathy Companies- Grunenthal GmbH, AlgoTherapeutix, Wex Pharmaceuticals Inc., and others.
* Chemotherapy-induced Peripheral Neuropathy Pipeline Therapies- LY3848575, Pregabalin, Oxaliplatin, Targin, Chemotherapy, Halneuron, Acetylcarnitine, and others.
* Chemotherapy-induced Peripheral Neuropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chemotherapy-induced Peripheral Neuropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chemotherapy-induced Peripheral Neuropathy Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chemotherapy-induced Peripheral Neuropathy Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Chemotherapy Induced Peripheral Neuropathy (CIPN): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chemotherapy Induced Peripheral Neuropathy (CIPN)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Capsaicin: Grunenthal GmbH
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ATX01: AlgoTherapeutix
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Companies
* Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Products
* Chemotherapy Induced Peripheral Neuropathy (CIPN)- Unmet Needs
* Chemotherapy Induced Peripheral Neuropathy (CIPN)- Market Drivers and Barriers
* Chemotherapy Induced Peripheral Neuropathy (CIPN)- Future Perspectives and Conclusion
* Chemotherapy Induced Peripheral Neuropathy (CIPN) Analyst Views
* Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chemotherapyinduced-peripheral-neuropathy-pipeline-appears-robust-with-4-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.